<DOC>
	<DOC>NCT01884259</DOC>
	<brief_summary>This multicentre, randomised Phase II Pilot Study evaluates the efficacy of docetaxel, cisplatin and 5-fluorouracil or Cetuximab, followed by Cetuximab with radiotherapy.</brief_summary>
	<brief_title>Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN</brief_title>
	<detailed_description>It will be evaluated whether 5-FU can be replaced by immunotherapy with cetuximab within a taxane/cisplatin-containing induction-chemotherapy scheme for advanced carcinoma of the head and neck. As 5-FU causes severe mucosal toxicities which are added to known toxicities of cisplatin, a combination-therapy with reduced toxicities and same efficacy would be a acceptable alternative to patients.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Laryngeal Diseases</mesh_term>
	<mesh_term>Laryngeal Neoplasms</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirmed local advanced squamous cell carcinoma of the Larynx, Hypopharynx, Oropharynx or Cavum oris stage III and IV One measureable lesion (CT oder MR) Age 18 75 (including) Performance Score ECOG 0 1 Exclusion Criteria selected: Distant metastases ECOG Score &gt;1 Prior radiation (Head and neck area) Creatinin Clearance below 60 ml/Âµl Acute infections Neuropathy grade 3 or 4 Myocardial Infarction within the last 12 months Acute coronary syndrome or othe clinically significant cardiovascular diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>local advanced squamous cell carcinoma</keyword>
	<keyword>Larynx</keyword>
	<keyword>Hypopharynx</keyword>
	<keyword>Oropharynx</keyword>
	<keyword>Cavum oris</keyword>
	<keyword>docetaxel</keyword>
	<keyword>cisplatin</keyword>
	<keyword>5-fluorouracil</keyword>
	<keyword>Cetuximab</keyword>
</DOC>